Company registration number 12420452 (England and Wales)
LANSDALES PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
LANSDALES PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
LANSDALES PHARMA LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
3
440,213
466,108
Tangible assets
4
37,790
47,132
478,003
513,240
Current assets
Stocks
49,989
46,896
Debtors
5
133,261
132,367
Cash at bank and in hand
452,861
238,973
636,111
418,236
Creditors: amounts falling due within one year
6
(883,401)
(803,996)
Net current liabilities
(247,290)
(385,760)
Total assets less current liabilities
230,713
127,480
Creditors: amounts falling due after more than one year
7
(17,940)
(26,551)
Provisions for liabilities
(9,447)
(11,783)
Net assets
203,326
89,146
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
203,226
89,046
Total equity
203,326
89,146
LANSDALES PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 JANUARY 2026
31 January 2026
- 2 -

For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 8 September 2026 and are signed on its behalf by:
Mr AA Hussain
Director
Company registration number 12420452 (England and Wales)
LANSDALES PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 3 -
1
Accounting policies
Company information

Lansdales Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, HA5 5QA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

LANSDALES PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 4 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Over the period
Fixtures and fittings
25% on reducing balance
Computers
25% on reducing balance
Motor vehicles
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

LANSDALES PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 5 -
1.10
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
5
5
3
Intangible fixed assets
Goodwill
£
Cost
At 1 February 2025 and 31 January 2026
517,898
Amortisation and impairment
At 1 February 2025
51,790
Amortisation charged for the year
25,895
At 31 January 2026
77,685
Carrying amount
At 31 January 2026
440,213
At 31 January 2025
466,108
LANSDALES PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 6 -
4
Tangible fixed assets
Leasehold land and buildings
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 February 2025
1
10,001
2,929
53,055
65,986
Additions
-
0
-
0
3,254
-
0
3,254
At 31 January 2026
1
10,001
6,183
53,055
69,240
Depreciation and impairment
At 1 February 2025
-
0
4,375
1,215
13,264
18,854
Depreciation charged in the year
-
0
1,406
1,242
9,948
12,596
At 31 January 2026
-
0
5,781
2,457
23,212
31,450
Carrying amount
At 31 January 2026
1
4,220
3,726
29,843
37,790
At 31 January 2025
1
5,626
1,714
39,791
47,132

Included within the net book value of the above asset is £29,843 relating to assets held under hire purchase agreements. The depreciation charged in the year in respect of such assets amounted to £9,948.

5
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
101,466
103,879
Other debtors
22,688
21,251
Prepayments and accrued income
9,107
7,237
133,261
132,367
6
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
140,818
135,606
Taxation and social security
66,250
45,445
Other creditors
676,333
622,945
883,401
803,996
LANSDALES PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 7 -
7
Creditors: amounts falling due after more than one year
2026
2025
Notes
£
£
Obligations under finance leases
17,940
26,551
8
Related party transactions
2026
2025
Amounts due to related parties
£
£
Other related parties
577,216
577,216

The above disclosed amount is included within the other creditors due in one year. The loan is unsecured, interest free and repayable on demand.

 

2026-01-312025-02-01falsefalsefalse08 September 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr AA HussainMrs SP Khaliq124204522025-02-012026-01-31124204522026-01-31124204522025-01-3112420452core:Goodwill2026-01-3112420452core:Goodwill2025-01-3112420452core:FurnitureFittings2026-01-3112420452core:ComputerEquipment2026-01-3112420452core:MotorVehicles2026-01-3112420452core:LandBuildings2025-01-3112420452core:FurnitureFittings2025-01-3112420452core:ComputerEquipment2025-01-3112420452core:MotorVehicles2025-01-3112420452core:CurrentFinancialInstrumentscore:WithinOneYear2026-01-3112420452core:CurrentFinancialInstrumentscore:WithinOneYear2025-01-3112420452core:Non-currentFinancialInstrumentscore:AfterOneYear2026-01-3112420452core:Non-currentFinancialInstrumentscore:AfterOneYear2025-01-3112420452core:CurrentFinancialInstruments2026-01-3112420452core:CurrentFinancialInstruments2025-01-3112420452core:ShareCapital2026-01-3112420452core:ShareCapital2025-01-3112420452core:RetainedEarningsAccumulatedLosses2026-01-3112420452core:RetainedEarningsAccumulatedLosses2025-01-3112420452bus:Director12025-02-012026-01-3112420452core:Goodwill2025-02-012026-01-3112420452core:LandBuildingscore:LongLeaseholdAssets2025-02-012026-01-3112420452core:FurnitureFittings2025-02-012026-01-3112420452core:ComputerEquipment2025-02-012026-01-3112420452core:MotorVehicles2025-02-012026-01-31124204522024-02-012025-01-3112420452core:Goodwill2025-01-3112420452core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-01-3112420452core:FurnitureFittings2025-01-3112420452core:ComputerEquipment2025-01-3112420452core:MotorVehicles2025-01-31124204522025-01-3112420452core:LandBuildingscore:LeasedAssetsHeldAsLessee2026-01-3112420452core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-02-012026-01-3112420452bus:PrivateLimitedCompanyLtd2025-02-012026-01-3112420452bus:SmallCompaniesRegimeForAccounts2025-02-012026-01-3112420452bus:FRS1022025-02-012026-01-3112420452bus:AuditExemptWithAccountantsReport2025-02-012026-01-3112420452bus:Director22025-02-012026-01-3112420452bus:FullAccounts2025-02-012026-01-31xbrli:purexbrli:sharesiso4217:GBP